Piroxicam Treatment Protects Mice from Lethal Pulmonary Challenge with Pseudomonas Aeruginosa
Overview
Authors
Affiliations
The effect of treatment with the nonsteroidal anti-inflammatory agent piroxicam on leukocyte migration to the lungs was investigated after aerosol administration of sublethal doses of Pseudomonas aeruginosa to mice. Piroxicam decreased, in a dose-related fashion, the polymorphonuclear leukocyte recruitment to, and the degree of perivascular and peribronchial infiltration in, the lungs. Piroxicam treatment also protected the animals in a dose-dependent manner from challenge with lethal doses of P. aeruginosa. The effect of piroxicam was not related to direct action of the drug on the microorganisms. Piroxicam treatment maintained the animal's pulmonary defenses against infection while diminishing inflammatory responses against P. aeruginosa, an occurrence decreasing the potential for tissue damage due to phagocytes migrating from circulation.
Beasley J, Dorjsuren D, Jain S, Rath M, Tieghi R, Tropsha A bioRxiv. 2025; .
PMID: 39896648 PMC: 11785035. DOI: 10.1101/2025.01.17.633658.
Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M J Clin Med. 2019; 8(6).
PMID: 31163625 PMC: 6617416. DOI: 10.3390/jcm8060786.
E-prostanoid 2 receptor signaling suppresses lung innate immunity against Streptococcus pneumoniae.
Aronoff D, Bergin I, Lewis C, Goel D, OBrien E, Peters-Golden M Prostaglandins Other Lipid Mediat. 2012; 98(1-2):23-30.
PMID: 22575745 PMC: 3350638. DOI: 10.1016/j.prostaglandins.2012.03.002.
Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation.
Ballinger M, McMillan T, Moore B Arch Immunol Ther Exp (Warsz). 2007; 55(1):1-12.
PMID: 17221337 PMC: 3313470. DOI: 10.1007/s00005-007-0001-2.
Carsenti-Etesse H, Farinotti R, Durant J, Roger P, de Salvador F, Bernard E Eur J Drug Metab Pharmacokinet. 1998; 23(3):357-66.
PMID: 9842977 DOI: 10.1007/BF03192294.